Ixekizumab patients, who all started with an introductory 160-mg dose, were all more likely than placebo patients to achieve the primary endpoint of the study: a 20% reduction in disease burden as measured by American College of Rheumatology criteria (an ACR20 response) by week 24.
Erelzi, a biosimilar of Enbrel (etanercept), has received FDA approval. Biosimilars are defined by the organization as being “highly similar to an FDA-approved biological product” while demonstrating “clinically meaningful differences in terms of safety and effectiveness.”
As one of the leading educational institutions on the island of Grenada, St. George's University plays a unique role not only in helping the students that come to the school to learn but also those who have already called the island home.
Whether medical students learn their craft at the most established institutions or newer schools around the world their ultimate goal is the same, to help the patient in front of them when they enter practice.